Your browser doesn't support javascript.
loading
Association of High Neutrophil-to-Lymphocyte Ratio With Poor Outcomes of Pembrolizumab Therapy in High-PD-L1-expressing Non-small Cell Lung Cancer.
Hasegawa, Tsukasa; Yanagitani, Noriko; Utsumi, Hirofumi; Wakui, Hiroshi; Sakamoto, Hiroaki; Tozuka, Takehiro; Yoshida, Hiroshi; Amino, Yoshiaki; Uematsu, Shinya; Yoshizawa, Takahiro; Uchibori, Ken; Kitazono, Satoru; Horiike, Atsushi; Horai, Takeshi; Kuwano, Kazuyoshi; Nishio, Makoto.
Affiliation
  • Hasegawa T; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yanagitani N; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Utsumi H; Division of Respiratory Diseases, Department of Internal Medicine, the Jikei University School of Medicine, Tokyo, Japan.
  • Wakui H; Division of Respiratory Diseases, Department of Internal Medicine, the Jikei University School of Medicine, Tokyo, Japan.
  • Sakamoto H; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Tozuka T; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yoshida H; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Amino Y; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Uematsu S; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Yoshizawa T; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Uchibori K; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kitazono S; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Horiike A; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Horai T; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Kuwano K; Division of Respiratory Diseases, Department of Internal Medicine, the Jikei University School of Medicine, Tokyo, Japan.
  • Nishio M; Department of Thoracic Medical Oncology, the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan mnishio@jfcr.or.jp.
Anticancer Res ; 39(12): 6851-6857, 2019 Dec.
Article in En | MEDLINE | ID: mdl-31810952
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / B7-H1 Antigen / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Res Year: 2019 Type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / B7-H1 Antigen / Antineoplastic Agents, Immunological / Lung Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Res Year: 2019 Type: Article Affiliation country: Japan